EICHORCondition: Pharmacokinetic Analysis · Sponsor: PureTech
Sponsor, CRO or site team? See where this study is running → — listed sites, countries and recruiting context. Everything below is written for patients and caregivers.
A three-part, randomized, double-blind study in healthy older adults to identify a dose of deupirfenidone for further clinical study.
This description comes directly from the study's public registry record.
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
* Male or female between 60 and 80 years old (inclusive) at the time of Screening. * In good general health at Screening, free from clinically significant laboratory values, or clinically significant unstable medical, surgical, or psychiatric illness, as determined by the Investigator. Subjects with mild, chronic, stable disease and on stable medication could be included if deemed medically prudent by the Investigator. * Has a body mass index (BMI) between ≥18.0 and ≤50.0 kg/m2 at Screening.
Reproduced word-for-word from the public registry record — the study team can answer questions about it.
| Collaborative Neuroscience Network, LLC. | Long Beach, California, United States | — |
| Accel Research Sites | Lake Mary, Florida, United States | — |
| Hassman Research | Berlin, New Jersey, United States | — |
This study lists sites in the areas below. Each link shows other recruiting studies near that city, from the public registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07456800